R&D pipeline for future medical-grade skincare: Mineral Complexions™ Post-Procedure Shield SPF30 is the first step in a broader innovation roadmap. Cosmectology’s R&D pipeline is focused on building a portfolio of medical-grade, technology-enabled products that serve practitioners, patients, and global partners.
1. Expanding the Product Family
Over the 2025–2027 horizon, our R&D objectives include:
- complementary post-procedure products that support barrier repair and hydration
- daily-use mineral SPF formulations optimized for different skin types and tones
- advanced textures that balance high zinc concentrations with elegant wear
- targeted pre- and post-care solutions for specific procedures
Each new product will follow the same discipline applied to Mineral Complexions™: regulatory alignment, laboratory validation, and traceability integration.
2. Deepening Technology Integration
On the technology side, we are focused on:
- strengthening our digital traceability architecture
- enhancing data flows between production, distribution, and clinics
- integrating analytics that help clinics better understand product usage trends
- preparing for future interoperability with external compliance and inventory systems
This positions Cosmectology not only as a product company, but as a science and data partner for clinics and distributors.
3. Innovation Goals and Partnerships
To accelerate our roadmap, we are actively exploring collaborations with:
- formulation and clinical research partners
- Canadian and international innovation programs
- export and distribution networks
- health and med-tech ecosystems
Our goal is clear:
By 2027, Cosmectology aims to be recognized as a trusted, innovation-driven Canadian leader in medical-grade skincare—with a product line and technology backbone that can scale across Canada, the U.S., the EU, and beyond.
Vanessa I.
President
Cosmectology Enterprises Inc.
president@cosmectology.com
